glp-1 receptor agonists in idiopathic intracranial hypertension medications and pseudotumor cerebri / #pseudotumorcerebri #iih GLP-1 programs the neurovascular landscape:

Treatment with GLP-1 Receptor Agonists

The competitive landscape intensifies as pharmaceutical giants invest heavily in next-generation GLP-1 analogs with improved efficacy profiles

Wing et al., 2011)

Disproportionality analysis A sequential approach was adopted to systematically address major confounders: (1) An exploratory disproportionality approach comparing GLP-1RAs with all other drugs reported in the FAERS database, using venlafaxine as the positive control and empagliflozin/orlistat as the negative control

Manufacturers generally warn against using these drugs if a person has a personal or family history of medullary thyroid carcinoma, a type of thyroid cancer, or multiple endocrine neoplasia syndrome type 2 (MEN 2), an endocrine system condition

Diabetologia 2009